ArticleFrontiers in oncology2022
Development and Validation of the Breast Cancer Scale QLICP-BR V2.0 Based on Classical Test Theory and Generalizability Theory.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 7 citations in OpenAlex.
- Development of the Short Form of the Specific Module of QLICD-BPH (V2.0) for Assessing Quality of Life with Benign Prostatic Hyperplasia by Classical Test Theory, Item Response Theory, and Generalizability Theory.European urology open science · 2026Article
- Exploring multiple minimal clinically important differences for the esophageal cancer scale QLICP-ES (V2.0) based on anchor-based and distribution-based methods.Scientific reports · 2026Article
- A Longitudinal Study on Development and Validation of the Prostate Cancer Scale Among the System of Quality of Life Instruments for Patients with Cancer (QLICP-PR V2.0) Based on Classical Test Theory and Generalizability Theory.Annals of surgical oncology · 2026Article
- Development and Validation of a Multidimensional Scale to Assess Cancer Health Education Outcomes in Patients.Patient preference and adherence · 2026Article
- Development and validation of the renal cancer scale among the system of quality of life instruments for cancer patients QLICP-RE (V2.0): a multicenter longitudinal study.BMC nephrology · 2025Article
- Development and validation of the AIDS scale among the system of quality of life instruments for chronic diseases (QLICD-HIV V2.0).BMC infectious diseases · 2025Article
- Development and validation of the NCC-BC-A scale to assess patient-reported outcomes for breast cancer patients in China.Cancer innovation · 2024Article
- Item analysis on the quality of life scale for anxiety disorders QLICD-AD(V2.0) based on classical test theory and item response theory.Annals of general psychiatry · 2024Article
- Quality of life and its related-influencing factors in patients with cervical cancer based on the scale QLICP-CE(V2.0).BMC women's health · 2024Article
- Health-related quality of life and its influencing factors in patients with breast cancer based on the scale QLICP-BR.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to develop and validate the breast cancer scale among the system of quality-of-life instruments for cancer patients (QLICP-BR V2.0). Methods: Programmed decision procedures and theories on instrument development were applied to develop QLICP-BR V2.0. A total of 246 breast cancer inpatients were investigated using QLICP-BR V2.0 from hospital admission until discharge. The reliability, validity, and responsiveness of the QLICP-BR V2.0 scale were evaluated by using the classical test theory combined with the generalizability theory (GT), including correlation analysis, multi-trait scaling analysis, factor analyses, Results: The test-retest reliability of the total scale is 0.79, the Cronbach coefficient is 0.85, and the intra-class correlations coefficient is 0.88. The item-domain correlation analysis showed that the correlation coefficient between items and their own domain is greater than that with other domains except of item GSO4. The exploratory factor analysis showed that three principal components are obtained in the specific module. The outcome of the factor analysis coincides substantially with our theoretical conception. The score difference of each domain of the scale and the total scale before and after treatment is statistically significant ( Conclusion: QLICP-BR V2.0 exhibited reasonable degrees of validity, reliability, and responsiveness according to classical test and the generalizability theory. The number of items in the scale is appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.